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International guidelines recommend that health care clinicians communicate with 
people with MND and their family members about non-invasive ventilation (NIV) and 
percutaneous gastrostomy tube (PEG) prior to or at the onset of respiratory symptoms. This 




Interpretive Description methodology was employed for this study, which was set in 
two Australian states. Nineteen clinicians experienced in caring for people with MND, six 
relatives of recently deceased people with MND and one person with MND participated in 
semi-structured in-depth interviews. Clinicians’ accounts of their NIV and PEG-related 
communications were compared to the family member participants’ recollections of their own 
discussions with clinicians on these topics. Data were analysed thematically.   
 
Results 
Six major themes emerged from data analysis that together capture the factors that 
impact practitioner-patient-family communications about NIV and PEGs. Some clinicians 
were unaware of MND international guidelines particularly communicating the burdens or 
possible withdrawal of NIV or found them challenging to implement. Consequently, family 
participants reported that they and their relatives with MND found clinicians’ communication 
on these topics inadequate. This led to them ‘topping up’ their knowledge from less 
authoritative sources, predominantly the internet.  
Discussion 
Clinicians’ lack of awareness of the international guidelines and discomfort about 
discussing the benefits and burdens of NIV and PEGs means that health care users and 
their loved ones are at risk of being unprepared for the consequences of commencing, using 
and ceasing NIV. Further research to discover how best to implement the evidence-based 
guidance on this topic into practice is warranted.  
 
Keywords: Motor Neuron(e) Disease, amyotrophic lateral sclerosis, palliative Care, 
noninvasive ventilation, communication  
 
Introduction 
Motor Neurone Disease (MND), the most common form being Amyotrophic Lateral 
Sclerosis (ALS), is a progressive neurological condition that adversely affects muscular 
control 1, 2. Muscles weaken, causing breathing, communication and swallowing difficulties, 
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and ultimately respiratory failure and death. Respiratory failure is often a complication of 
respiratory infection secondary to aspiration. The duration of survival from the onset of 
symptoms is 20-48 months 3. 
The global incidence of MND / ALS was calculated in 2019 as ranging between 0.6-
3.8 per 100 000 person-years, and as proportionally higher in Europe (2.1-3.8 per 100 000 
person years) than in Asia (0.8-1.2 per 100 000 person years)4 . This represents an overall 
rise in recent years: in 2005 the estimate of the worldwide occurrence was 1.5 – 2 per 
100,000 per year 5, with an approximate lifetime risk of developing the disease of 1 in 800 6, 
and a subsequent systematic review of European literature suggested this had increased to 
2.08 per 100,000 four years later7.  
In June 2019 more than 2,000 people were known to have MND in Australia (60% 
male and 40% female). At that time two people were diagnosed with MND and two people 
died from MND in Australia each day. The prevalence of MND in 2015 was 8.7 per 100,000 
people or 1 per 11,434 Australians. The global increase in cases noted earlier appears to 
include Australia: In 2016, 791 persons died from MND in Australia compared to 592 in 2001 
8MND is a progressive, terminal neurological disease for which there is no known cure and 
no effective treatment 8.  
The disease presents a number of care-related challenges, beginning with it being 
extremely difficult to diagnose because symptoms may be isolated and unexplained 9 and 
compounded by the progressive loss of limb use and the ability to speak, swallow and 
breathe, all while the person’s mind and senses usually remain intact. As respiratory 
muscles become progressively affected, non-invasive ventilation (NIV) is usually offered to 
alleviate distressing respiratory symptoms. There is general agreement that in addition to 
symptom relief, NIV can improve survival, particularly if there is no bulbar involvement 9, 10. 
The consideration of a feeding tube via Percutaneous Endoscopic Gastrostomy (PEG) to 
maintain nutrition and hydration is recommended prior to the onset of respiratory symptoms 
due to a potential increase in respiratory complications with later insertion 9. However, as 
PEG tubes offer little or no extension of life, have minimal effect on relieving aspiration and 
can be uncomfortable, some people with MND refuse PEGs 11.  
The seminal clinical care resource for diagnosis and care of people with MND is the 
evidence-based guidance published by the UK National Institute for Health and Care 
Excellence (NICE) in 2016. These guidelines provide clear recommendations for recognition 
of the disease, referral to specialist services, how information and support should be 
provided at diagnosis, determining cognitive capacity, care planning care that takes account 
of various prognostic factors as well as psychological and social care needs, how care 
should be organised, end of life planning, and symptom management (including key points 
to include in PEG and NIV-related conversations). Early discussion of the implications, 
benefits and burdens of both NIV and PEG tubes is recommended in this and other 
international consensus evidence-based guidelines 9, 12, however the extent to which this 
guidance has translated into practice is underreported 13.  
Research into the experiences of people with MND and their families frequently 
suggests that clinician communication is generally inadequate, particularly when delivering 
the diagnosis 14-16. For people with MND, deteriorating health and increasing symptoms 
mean that treatment decisions involving potential life-sustaining technologies are often faced 
early in the person’s clinical care. Thus, accurate information about the benefits and burdens 
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as well as the life extension limitations of such treatments needs to be communicated early 
and revisited as the disease progresses9. A potential complication lies in how MND is 
perceived and characterised by clinicians. The variants of MND and the sometimes 
unpredictable timing of progression of the disease can mean that the point at which a person 
is perceived as having a chronic and terminal disease becomes difficult to predict. The point 
at which chronic illness becomes defined as terminal may confuse the timing of support 
required by the person with MND and their caregivers17. In addition, multiple health 
professionals and several different service organisations may be involved with the person 
with MND from diagnosis, which has the potential for missed communications, confusion and 
conflicting messages. 
The problem this study thus sought to address was that it is unknown whether 
clinicians implement best evidence-based guidance in their communications about end-of-life 
treatment choices with people with MND and their family members. The objectives of the 
study were to describe clinician communication surrounding NIV including end-of-life 
choices, to understand how clinicians check the level of understanding among patients and 
family members of the benefits, burdens and potential of NIV withdrawal prior to NIV 
commencement, and to compare the content, process and outcomes of NIV communication 
as described by clinicians and families of people with MND within this study against the 
currently available recommendations relating to commencement and withdrawal of NIV and 
related end-of-life care options. To that end, the overarching research question we sought to 
answer was ‘How effective are clinicians’ efforts in facilitating patients’ and family members’ 
understanding of the options regarding PEG and NIV, and of the value and possible burdens 
of those treatments?   
 
Methods  
Design. This study was conducted using Interpretive Description (ID) methodology18, 19. ID 
was developed principally as a process for obtaining knowledge within the context of clinical 
events to elicit change9 and incorporates aspects from grounded theory and 
ethnomethodology in its approach to purposive data collection10. The ID process and 
outcome enables light to be thrown on a collection of expressed truths to inform a practical 
change, and for this reason it was selected as the most appropriate approach for 
investigating communication between clinicians, patients and family members.  The purpose 
of the study was to answer the following research question: ‘How effective are clinicians’ 
efforts in facilitating patients’ and family members’ understanding of the options regarding 
PEG and NIV, and of the value and dis-benefits of those treatments?’ and to address there 
related objectives (to describe clinician communication surrounding NIV including end-of-life 
choices, to understand how clinicians check the level of understanding among patients and 
family members of the benefits, burdens and potential of NIV withdrawal prior to NIV 
commencement, and to compare the content, process and outcomes of NIV communication 
as described by clinicians and families of people with MND within this study against the 
currently available recommendations relating to commencement and withdrawal of NIV and 
related end-of-life care options).  
Setting 




Purposeful sampling 18 was employed to ensure the participation of informants with 
knowledge of the phenomenon of interest. The sample included healthcare clinicians 
involved with the respiratory care of MND, NIV initiation, NIV withdrawal and end-of-life care, 
and relatives of deceased people with MND who had used NIV. Uninvited, one person with 
MND who was using NIV requested inclusion in order to share experiences. Therefore, one 
interview was conducted with a person with MND. These data were used to illuminate and 
contextualise the two primary data sets.  
Additional participant characteristics are provided in Tables 1 and 2.    











for overall care 
Part of 
structured MDT 
F 1/2 No Regional/rural Unclear: GP and 
neurologist 
No 
F 3 Yes Regional Neurologist and 
GP 
Yes 
F 4 No Rural GP No 
 
F 5 Yes Remote GP No 
 
F 6 Yes Rural  GP No 
 
P 1 No Regional  Neurologist Intermittently 
 





















Years (y) of MND experience 
and % of workload dedicated 





































Sometimes Regional and 
rural 





Yes Regional and 
rural 




















Palliative Care Nurse 14 y 
Intermittent 
Yes Regional 
C10 Palliative Care Nurse 5 y 
Intermittent 
Yes Regional and 
rural 
C11 Respiratory Specialist 
(Medical Practitioner) 




5% of annual work Yes Regional 
 
 
C13 Social Worker 
 
approx. 30 MND pts ongoing Sometimes  
Regional 


































approx. 30 MND/year 
No  
Regional 













Clinician and family participants with experience of MND care were invited to 
participate through palliative care services, hospitals, support organisations and specialist 
palliative centres care via email, letter, newsletter or face-to-face invitation by staff members. 
An information sheet and consent form were sent to those who expressed interest. All 
participants who requested the information sheet subsequently agreed to be interviewed. No 
participant who consented to be interviewed later withdrew.  
Data collection 
Data were obtained through single audio-recorded one-to-one semi-structured 
interviews with individuals that were conducted by [the first author], who is both a senior 
palliative care nurse and researcher with extensive training and experience in interviewing, 
communication and information gathering. All clinician interviews took place in a private 
room within their workplace or via videoconference or telephone. All family participants 
chose home interviews. No family participant was known to the interviewer prior to 
recruitment into the study.  
Clinician participants were asked open-ended questions about what/when they 
communicated to people with MND and their families about NIV, its limitations, its benefits 
and its burdens. They were asked how they communicated the withdrawal of NIV, early 
palliative care referral, end-of-life choices, Advance Health Directives (AHD) and PEGs. 
Further, clinicians were asked how they ascertained understanding of the information by the 
person with MND and their families. 
Family member participants and the person with MND were asked to consider two 
points in time: first when respiratory symptoms commenced and second when it became 
necessary to consider end-of-life care options. They were asked what they recalled at each 
time-point about the communication about PEG and NIV, and NIV withdrawal. They were 
also asked what they understood about the need for early palliative care referral, benefits 
and possible burdens of NIV and PEGs and whether AHDs were encouraged by clinicians. 
All interviews were terminated when the participant indicated they had nothing further to add, 
and each participant received a copy of their transcribed interview and all approved its 
inclusion in data analysis 20. Data collection ceased when saturation of themes was 
achieved. 
Data analysis 
Participant de-identification by the principal investigator occurred prior to the 
interview transcription, through a pseudonym allocation (e.g. P1). The initial phase of the 
data analysis identified emergent words and phrases (‘codes’) that related to the research 
questions. The NVivo 11™ software package was used to assist the process of coding the 
developing sub-themes and themes (Figure 1). When no new data were provided, saturation 











Trustworthiness of the research was assured primarily by designing interview 
questions which encouraged participants to describe conversations they had with clinicians 
surrounding the initiation, use and ultimate removal of NIV in patients with MND 20. Several 
additional measures were implemented to ensure trustworthiness of the study. First, the 
transcribed interviews were returned to the participants for validation and approval for use in 
the data analysis20-22. Second, all interviews were analysed by the first author, and three 
were also analysed independently by author two; similar themes were derived by both. Third, 
themes developed from analysis were discussed by all members of the research team and 
consensus reached. Fourth, an audit trail that includes interview transcripts, analysis of data, 
process notes, notes about difficulties encountered, personal notes and draft documents 
have been kept 21-23. 
 
Ethical considerations 
Approval to conduct the study was obtained from the Human Research Ethics 
Committees at Edith Cowan University (ECUHREC Number 12099), Silver Chain Hospice 
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Nursing WA, two St John of God Hospital sites in WA and the Neurological Council of WA. 
Participants were offered the opportunity to ask questions and informed of their right to 
withdraw at any time until data analysis. Information on counselling services was provided in 
case of distress following the discussion. Participants who agreed to be interviewed and 
audio-recorded signed a consent form. 
Results  
Nineteen clinician participants were interviewed, eight of whom had experience of 
early respiratory symptoms in people with MND and ten of palliative or end-of-life care. Six 
family member participants and one person with MND were interviewed, all from Western 
Australia. Twenty nine hours and thirty minutes of data were collected from which six major 
themes  emerged when data analysed: ‘Experience of clinicians with NIV withdrawal’; 
‘Timing and content of communication about the benefits and burdens of NIV, PEGs and 
end-of-life choices’; ‘Time allocated for communicating and discussing end-of-life choices’; 
‘Early referral to palliative care and family understanding of palliative care’; ‘Communication 
within a multi-disciplinary team’; and ‘Patient and family communication and understanding‘. 
 
Experience of clinicians with NIV withdrawal  
 All the clinician participants interviewed had many years of experience of 
communicating with patients and relatives about end-of-life decisions (4.5-22 years), with 12 
of the 19 clinicians having had at least 10 years in practice. Significant practice experience 
did not appear to make discussions about NIV withdrawal easier or more likely for clinician 
participants, and despite their knowledge of the best practice evidence, many clinicians 
reported difficulty giving ‘good’ information when there was uncertainty about the 
deterioration trajectory. 
The complex challenges of deciding the exact protocol and timing for NIV withdrawal, 
assessing family readiness for the information and maintaining comfort until death, were 
described by several clinicians as particularly dreaded. Participant C11, a medical 
practitioner specialising in respiratory care, exemplified this in the following quote:  
 [it’s] bloody awful, because – the when, how, pharmacotherapy, you know. What do you do? 
Do you necessarily withdraw NIV or do you let people die on NIV? …  [And] I suspect it’s 
enormously difficult from the family’s point of view unless the conversations leading up to it 
have been really good and really clear.  
C19 (palliative care consultant): I think one of the barriers is sensitivity or worrying that 
that’s – even having that conversation is going to upset the patient or the family. 
One of the most noted barriers clinician participants experienced in this regard was patient 
denial: 
 
C4 (respiratory specialist): [Often you hear] “Oh, I just don’t want to think about it.  I don’t 
want to know.”  So that can be a bit of a challenge that their defence mechanism, their way 
of coping is one of, “That’s later on,” denial.   
Family members’ experiences of this uncertainty and vagueness in clinicians about 
withdrawal of NIV meant that they then didn’t have enough information to contribute an 
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opinion about care decisions. F5, who self-reported as having high health literacy and 
knowing what questions to ask, said:  
 Because in these appointments you – particularly with a neurologist who gives you an 
overall reading on how the whole thing’s going, if you don’t ask questions, and you’re not an 
assertive sort of person, sometimes I think you could walk out missing a lot, do you know 
what I mean? 
In some cases, no-one ever discussed NIV withdrawal with patients and families, and the 
impact of this can have profoundly devastating and long-lasting effects: 
F1 (family): I think now, I would have opted for [NIV withdrawal] because Mum was so 
uncomfortable and so suffering that I would have opted to say, “Let’s, you know, ditch that…” 
– and I think now Dad would have taken that option. But from what we knew, and what we – 
while we were going through it, I don’t think we would have done any different to what we did 
do. But do you know what I mean, hindsight’s a wonderful thing . . .  
I regret – and you can use that as a quote if you want – but I regret the last three nights that 
mum had at home. It was awful for her, for dad, for me. It was just – still burned in my 
memory, and it’s hard to sort of go away.’ 
 
Timing and content of communication about the benefits and burdens of NIV, 
PEGs and end-of-life choices 
Many of the clinician participants reported that the timing for raising the topic of the end of 
life and NIV withdrawal with patients and family members challenging. There was also 
confusion among clinicians about who was responsible for these communications, and 
concern that patients might not be prepared for them. Most of the specialist clinicians 
interviewed said they tried to ascertain how much the person with MND and their family 
knew about the course of the disease and tailored the communication content accordingly.  
C4 (respiratory specialist): I mean, you’re talking about end-of-life issues, which 
many health practitioners are uncomfortable talking about. And then I would think 20 
to 40 to 50 per cent of patients will tend to say, “Well, we don’t want to talk about 
that. We’ll think about it when the time comes.” So even though you may have the 
best intentions of trying to have all this out in the open and discussed and 
documented, it’s not always the case that the patients wish to discuss it. 
C2 (palliative care specialist): We’re palliative care doctors. We like to think that we’re 
good at communicating, but I think, I acknowledge, that often families need to hear things 
multiple times. 
Further, most clinician interviewees spoke about being sensitive to the contradictory nature 
of the complex information relating to withdrawal of NIV and what this means to patients and 
families:  
C12 (physiotherapist): You’re offering them something that potentially may treat their 
symptoms, but then at the same time saying, “Oh, by the way, you know, let’s also talk 
about, you know, end of life as well.” 
C19 (palliative care consultant): I guess the pros is a very transparent discussion, isn’t it, 
that you’re actually, at the time of putting the – sorry, of starting the machine, the NIV, you’re 
also talking about the possibility of withdrawal.  I can see the merit of that.  I guess on the 
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other hand – I’m just thinking of the emotional dimension of that, and I guess that may – I’d 
have to think of the sensitivity of that conversation at that time.   
C14 (MND clinical nurse specialist): It’s a conversation that we dread, I think, to remove it, 
because the breathing is so essential to stay alive. And there’s no good or there’s no best 
timing for it.  
Compounding clinicians’ uncertainty about the right time for these discussions, many 
recognise the preservation of hope can underlie a family’s wish to avoid discussing the end 
of life. The following describes the experience of how one clinician dealt with it: 
F3 (family): And then when [the person with MND] was, you know, eventually diagnosed, 
we – by that stage we’d been reading up on best practice and, you know, we knew all about 
the multi-disciplinary team approach, etcetera. And [the health care professional’s] response 
was, “Oh, you’re not going to need [end of life care] for a long, long time. And don’t talk to 
[patient and carer support organisation] - they’re way too negative. I’ll see you in a year.” 
Time allocated for communicating and discussing end-of-life choices  
Insufficient time for these conversations was reported by the majority of the clinicians 
interviewed for a range of reasons, as participant C2 (palliative care consultant) said: 
Time, you know. We’re all very time poor, and these conversations take time, need to be re-
visited, the patient’s cognitive ability, family issues. You know, conflict within a family. All 
sorts of things come into play. 
Participant C13 (social worker) elaborated further on the complicating issue of patients’ 
deteriorating cognitive ability:  
What concerns me sometimes with that [frontotemporal dementia] is that they [person with 
MND] don’t have a deeper understanding of the situation [as they would] if they didn’t have 
the FT [frontotemporal] [issues] happening, and it impacts on the carers, and that’s my 
concern 
With limited time for communication, clinicians described prioritising explanations about NIV-
related technicalities.  
C11 (respiratory specialist): [I focus on] how to set up the mask, how to set up the 
machine, how to plug it in, what to do if it leaks, what to do if they get rain out, what to do if 
they get this, that and something else…  a lot of the attention can be focused on the sort of 
practicality of the machine, and the sort of softer, more difficult conversations often get a little 
bit left to the side. 
The potential impact of this on patients and families, was that they may not have 
meaningful input to care:  
F6 (family): So, you know, some health professionals – I think periods of silence to listen to 
the client are needed without the health professional thinking, “I’ve got to tell them X, Y, 
Z…”.”  
Patient and/or family member reluctance or lack of readiness to ‘go there’ was also 
cited by clinical respondents as a barrier to having these conversations: 
C11 (respiratory specialist): There are some people that are willing to engage in this, and 
then there are other people where you can’t get them to engage in discussions about end-of-
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life care. And so, my goal is to do it early and to do it often until I feel like the patient and I, 
and family and I, are on the same page. But it’s sometimes, in the real practical world, more 
difficult than that.  
 
Early referral to palliative care and family understanding of palliative care 
 Many clinicians are reluctant to make or accept an early referral for people with MND 
to palliative care despite acknowledging this to be best practice, and sometimes the referral 
is declined by patients and/or family members. 
C4 (respiratory specialist): …ideally [I refer] all patients very early on, close to the time of 
diagnosis.  For various reasons some patients don’t want that. 
C2 (palliative care consultant): To be honest, most of my [MND] patients are referred very 
late, and we look after them for their end-of-life care.  
C16 (MND nurse consultant): …some pall. care teams are quite open to that [early 
intervention], but some pall. care teams have this weird definition period that they will not 
accept the patient until they have three months or less to live. 
F5 (family): She’s a specialist. And she said, “Now, I’ve got a letter here from your GP 
saying that you’re in denial about all this.” And we said, “We’re definitely not in denial about 
what’s happening to us. We’re just in denial that we need to see a palliative care team so 
early. That word ‘palliative’ over-shone whatever they were saying to us”  
F3 (family): [Palliative care] was discussed, and because … we now know that palliative 
care is really the only thing that you can do with motor neurone disease...but at that stage 
we were thinking “end of life”?? … and we were getting a bit paranoid.  
 
Communication within a multi-disciplinary team  
 Despite the recommendation that a multi-disciplinary team (MDT) approach is used, 
poor experiences of this were evident.  
C1 (palliative care consultant): I think my …fear is you can get so many teams of people 
involved. You’ve got specialist palliative care, GP and primary care, respiratory care, 
gastroenterologist who’s been involved with the PEG, the rehabilitation team, a neurologist 
who’s saying – you know, and the possibilities of confusion and misinformation are 
enormous…  I was going to say warfare [can occur]. 
Further, the health professionals interviewed described suboptimal communication between 
professionals: 
C4 (respiratory specialist): Look, I don’t think [communication between healthcare 
professionals is] particularly ideal at all. The communication we have is by letter, very 
occasionally a phone call. I don’t get a lot of – I mean, I write letters [to other clinicians], and 
I think I’m communicating, but I don’t feel I get a lot of feedback, unless there’s a big 
problem.  
In some cases, this was because there was no MDT: 
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C19 (palliative care consultant): Now, the interesting thing in the city is that not 
everywhere has a multi-disciplinary team. So, it’s a bit of a patchwork quilt, and indeed 
would be the whole of Australia a patchwork quilt. 
Gaps in communication within MDTs were found to be confusing for patients and families 
who needed to repeat the same information: 
F1 (family): We’d been to a few speechies [speech therapist] and dietitians, which Dad was 
getting confused about. So, I sort of explained to them that the dietitian was about the 
nutrients; the speechy was about … how to swallow, and the muscles in the neck. And Dad 
said, “We’re saying the same things to the same people.” 
 
Patient and family understanding  
 
 Denial and lack of understanding by some people with MND and their families about 
how quickly the disease can progress was expressed as a communication barrier by some 
clinician participants. Others noted that some people with MND and their families had been 
given little or conflicting information about the disease prior to seeing them. 
C2 (palliative care consultant): Some of them have clearly been told but don’t necessarily 
want to hear, understand or acknowledge, and some clearly have [had] very limited 
explanation. 
C1 (palliative care consultant): There was one person who was told it [MND] would – he’d 
known patients where it had burnt out after a few years and not progressed. So those 
patients – you know, it can be difficult because they may get mixed messages – different 
messages when they see a neurologist in a clinic who says, “Oh, you shouldn’t be thinking 
about a gastrostomy” when we’re already starting to talk about gastrostomy.  
Several of the health professionals in our study put forward that advice to people with 
MND regarding PEGs was unclear. 
 
C3 (palliative care specialist): Just touching on PEG tubes again, I think they’re often sold 
to people as more of a solution than they are, and I don’t think the difficulties of PEG tubes 
are adequately communicated… So, I think, you know, they’re kind of seen as an easy 
option when someone can’t swallow, and the reality of dealing with the other side of it isn’t 
always discussed as well. 
As with NIV, some clinician participants felt the decision about PEG tube insertion required a 
degree of understanding that some patients and families did not have: 
C15 (gastroenterologist): Understanding the medical complexities of PEG tube insertion 
needs a fair degree of health literacy and that can sometimes be a barrier. 
 
Discussion  
 This study sought to answer one overarching research question and fulfil three 
objectives, and those aims were achieved. Four key learnings emerged from this study. The 
first was that neither extensive practice experience nor knowledge of best practice evidence 
appear to make discussions about NIV withdrawal with people with MND and their families 
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easier or more likely for clinicians. The second was that knowing when the time is right to 
raise the topic of the end of life and NIV withdrawal with people with MND and family 
members is challenging for clinicians and once clinicians do commit to broaching these 
subjects, having adequate time for these very sensitive conversations is difficult to find. The 
third was that knowing who is responsible for initiating and continuing the conversation is not 
well understood by clinicians. Fourth was that family participants reported, likely as a result 
of all of the above, that they and their relatives with MND found clinicians’ communication on 
these topics to be inadequate. This led families to ‘top up’ their knowledge from less 
authoritative sources. The family participants in this study admitted to seeking clarifying 
information from the internet.  
 
 
 Clinician avoidance of difficult discussions seen in this research has been previously 
identified in MND 9, 13, 16, 24-26. International guidelines recommend early involvement of 
specialist palliative care and communication of end-of-life options 9, 12. This study has found 
clinicians make efforts to deliver end-of-life options, but not necessarily as the guidelines 
recommend 9, 12. The assumption that people will turn to the Internet to address their 
questions and fears may lessen the urgency clinicians feel to initiate such sensitive 
communication.  
 
The clinicians stated that time limitations affected their ability to comprehensively 
communicate the progressive nature of MND, the issues related to NIV and PEGs, treatment 
and end-of-life choices. It also limited their ability to ensure patient understanding of potential 
NIV withdrawal. Whilst all the bereaved families recognised the variability of the disease 
progression, all wished an idea of remaining life expectancy could have be given at symptom 
onset to enable some life planning 27, 28. The proposal to initiate NIV is an accepted trigger 
point at which clear discussion should occur. These discussions are often delayed by 
clinicians’ perception of a lack of patient or family readiness to engage in them and clinicians 
may not acknowledge the necessity of these discussions when the patient’s condition 
deteriorates29. Most of the clinicians in this research focussed on the positives surrounding 
symptom control rather than prolonging suffering by surviving longer. 
Although the most recent guidelines recommend referral to palliative care soon after 
diagnosis, this study found that in practice this did not usually occur, agreeing with an 
extensive systematic review 13. Both clinician and family participants agreed that determining 
the optimal time for referral to a palliative care service is complex 16, 30, 31. The palliative care 
specialists stated that they often had to clearly point out and belatedly discuss end-of-life 
options not discussed earlier 14, 27, 32, 33. Whilst some clinicians had minimal knowledge of the 
MND guidelines, others stated that the recommendations relating to early end-of-life 
communication were emotionally inappropriate. The bereaved families stated that early 
referral to a palliative care service was overwhelming, equating palliative with death, and it 
was apparent that the capabilities of palliative care had not been communicated or 
understood. Early symptom control communication enables patients and families time for 
informed discussion, to plan and prepare, and may prevent unwanted symptom control 
interventions such as NIV, gastrostomy tubes and the potential of invasive ventilation. Other 
studies tend to support these conclusions 31, 34. Several studies show that people with MND 
would like as much information as is available and the opportunity to discuss treatment 
options, believing that doctors should initiate such conversations 35, 36. 
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 Anecdotally, experience with communicating end-of-life choices to palliative care 
patients generally enhances a clinician’s ability to sensitively discuss options of care36. 
Clinical experience in palliative care and respiratory medicine was, therefore, anticipated to 
facilitate the difficult discussions soon after diagnosis. In this study, however, the experience 
of having prior involvement with withdrawal of NIV, an important aspect of MND, did not 
always make such communication easier for the clinicians37. 
 
The provision of structured multidisciplinary teams (MDT) was patchy within the area 
studied. Families and clinicians identified that communication barriers were pronounced 
when there is no structured MDT or single health professional responsible for patient care. 
Families with poor health literacy or knowledge of the health care systems lacked the skills 
or confidence to ask relevant questions relating to end-of-life and symptom control choices. 
The families and people with MND were aware time was not on their side and resented 
intrusion from many services and considered repetition of information to multiple people 
within an MDT as time-consuming, fatiguing and overwhelming 25, 38. 
Prolonging life and hope were considered important to the clinicians and influenced 
their decisions to discuss NIV withdrawal and end-of-life choices. None of the bereaved 
family participants recalled discussion about the potential of prolonging life in the context of 
possible suffering 32, 39, 40. Reflecting, some bereaved family participants said that their family 
member did suffer from not understanding that the NIV could be withdrawn.   
There are limitations to this study, including only one perspective of people with MND 
was included. Nonetheless, our questions about how communication about PEG and NIV is 
delivered as recommended by guidelines, how effective clinicians’ efforts are in facilitating 
patients’ and family members’ understanding of PEG and NIV, and of the value and dis-
benefits of those treatments were answered to some degree: we discovered that 
communications around end-of-life care options per se, and PEG and NIV in particular, are 
complicated by myriad of considerations and challenges that are not accounted for in the 
evidence-based guidance. 
How effective are clinicians’ efforts in facilitating patients’ and family members’ 
understanding of the options regarding PEG and NIV, and of the value and possible burdens 
of those treatments?  This research found the clinician preference for preservation of hope, 
lack of time for in-depth communication and the stigma of palliative care were all barriers to 
family understanding. The results will be of interest to all health care clinicians involved in 
the care of those diagnosed with a life-limiting disease for whom respiratory support may be 
helpful and their families, and to policy makers. The relevance of the study findings for 
patients and for carers is that the health service user perspectives reported can be used to 
inform practice improvements and further research, which is warranted to effectively capture 
the barriers to effective, timely and comprehensive end of life treatment options. Recent end-
of-life and clinical palliative care literature suggests that NIV is being increasingly employed 
as a palliating intervention for dyspnoea beyond MND to other progressive respiratory 
diseases such as lung cancer and emphysema 41. Understanding the gaps in 
communication, when discussions occur, how well the necessary information is 
communicated and comprehended by people with MND and their families is, therefore, 
becoming increasingly relevant to other diseases41, 42. The views of clinicians working with 
patients with chronic obstructive pulmonary disease and interstitial lung disease have been 
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